These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36059942)

  • 21. Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review.
    Lin R; Chen R; Chen Z; Hu L; Guo W; Zhang Z; Lin L; Chen H
    Front Oncol; 2021; 11():731572. PubMed ID: 34540698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report.
    Wu L; Fang C; Zhao W; Li D; Tang S; Li X; Ji M
    Ann Transl Med; 2022 Jan; 10(2):116. PubMed ID: 35282062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.
    Zhang Y; Sheng J; Kang S; Fang W; Yan Y; Hu Z; Hong S; Wu X; Qin T; Liang W; Zhang L
    PLoS One; 2014; 9(9):e107161. PubMed ID: 25222496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
    Wang Y; Li RQ; Ai YQ; Zhang J; Zhao PZ; Li YF; He WJ; Xia YX; Li WH
    Clin Transl Oncol; 2015 Sep; 17(9):727-36. PubMed ID: 26041721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.
    Kanazu M; Mori M; Kimura M; Nishino K; Shiroyama T; Nagatomo I; Ihara S; Komuta K; Suzuki H; Hirashima T; Kumagai T; Imamura F
    Thorac Cancer; 2021 Jan; 12(1):90-96. PubMed ID: 33124128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aumolertinib: A Review in Non-Small Cell Lung Cancer.
    Shirley M; Keam SJ
    Drugs; 2022 Apr; 82(5):577-584. PubMed ID: 35305259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
    Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
    Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
    Arrieta O; Cardona AF; Corrales L; Campos-Parra AD; Sánchez-Reyes R; Amieva-Rivera E; Rodríguez J; Vargas C; Carranza H; Otero J; Karachaliou N; Astudillo H; Rosell R;
    Lung Cancer; 2015 Feb; 87(2):169-75. PubMed ID: 25558790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
    Tsai TH; Wu SG; Chang YL; Wu CT; Tsai MF; Wei PF; Yang CH; Yu CJ; Yang PC; Shih JY
    J Thorac Oncol; 2012 Jun; 7(6):993-1000. PubMed ID: 22525557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
    Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic profiling reveals non-small cell lung cancer with common mutations of
    Bi X; Song P; Wang C; Zhang X; Liu C
    Transl Cancer Res; 2022 May; 11(5):1423-1428. PubMed ID: 35706785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare
    Zöchbauer-Müller S; Kaserer B; Prosch H; Cseh A; Solca F; Bauer MJ; Müllauer L
    Front Oncol; 2020; 10():593852. PubMed ID: 33575211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature.
    Yang Y; Zhang B; Li R; Liu B; Wang L
    Oncol Lett; 2016 May; 11(5):3546-3550. PubMed ID: 27123149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress.
    Castellanos EH; Horn L
    Curr Treat Options Oncol; 2015 Oct; 16(10):51. PubMed ID: 26364032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    Kaneda T; Yoshioka H; Tamiya M; Tamiya A; Hata A; Okada A; Niwa T; Shiroyama T; Kanazu M; Ishida T; Katakami N
    BMC Cancer; 2018 Jan; 18(1):6. PubMed ID: 29291705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
    Sheng M; Wang F; Zhao Y; Li S; Wang X; Shou T; Luo Y; Tang W
    Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea.
    Byeon S; Kim Y; Lim SW; Cho JH; Park S; Lee J; Sun JM; Choi YL; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Res Treat; 2019 Apr; 51(2):623-631. PubMed ID: 30049203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer.
    Hong W; Wu Q; Zhang J; Zhou Y
    Oncol Lett; 2019 Oct; 18(4):3887-3895. PubMed ID: 31516600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.